Avego BioScience Capital
Crossover fundActively deployingAlpharetta Β· Series BβLate Stage
Investment thesis
Avego invests across the healthcare continuum in companies developing and commercializing innovative products and services. The firm emphasizes evidence-based scientific evaluation, operational expertise from founder and executive backgrounds, personal capital alignment, and hands-on value creation. Avego seeks to accelerate growth through strategic support in R&D funding, corporate development, talent recruitment, and business development, with particular focus on high-quality science and sustainable competitive advantages in healthcare.
Source: firm website, verified Jul 21, 2026.
What they invest in
from 2 of 26 portfolio companiesBiotech Γ2Medical Devices Γ2
Investments Β· 26 tracked
founders shown can be your intro pathCaribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform. The company licenses foundational CRISPR-Cas9 intellectual property and advances drug candidates for patients with devastating diseases.
BiotechMedical Devices
Jennifer Doudna(Co-founder)Rachel Haurwitz(President and Chief Executive Officer, Co-founder)Martin Jinek(Co-founder)
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical Devices
Michael Kavanaugh(Founding Advisor)
Frequently asked questions
- What stage does Avego BioScience Capital invest at?
- Avego BioScience Capital invests at the Series B, Series C, Growth, Late Stage stages.
- What sectors does Avego BioScience Capital focus on?
- Avego BioScience Capital focuses on Biotech, Healthtech, Medical Devices.
- Where is Avego BioScience Capital located?
- Avego BioScience Capital is headquartered in Alpharetta, US.
- Does Avego BioScience Capital lead rounds?
- Yes, Avego BioScience Capital leads investment rounds.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
EQT Life Sciences is one of Europe's largest and most experienced life sciences investors, focusing on innovative companies developing therapeutics, medical devices, diagnostics, and healthtech globally. The firm has raised approximately 3.5 billion euros across 12 private funds and 3 investment strategies over its 30-year history.
Summit Partners is a growth-focused investment firm with over 41 years of experience investing in category-leading companies across technology, healthcare and life sciences, and growth products and services. The firm leverages a collaborative approach to support market leaders through both minority and majority investments.